Physician profile
William E Blaylock
NPI 1831207893
$12,936.82
in general payments reported to CMS, 2019-2025
53 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $428 · 2021: $996 · 2022: $2,342 · 2023: $910 · 2024: $5,832 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627 · Travel and Lodging: $4,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.59 |
| Travel and Lodging | $4,093.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $5,458.89 | 2021-2025 | Aquabeam System |
| Tolmar Pharmaceuticals, INC. | $1,067.10 | 2020-2022 | |
| Janssen Biotech, INC. | $998.10 | 2019-2025 | Erleada, Akeega, Balversa |
| Dendreon Pharmaceuticals LLC | $562.15 | 2021-2025 | Provenge |
| Endo Pharmaceuticals INC. | $487.63 | 2019-2024 | Xiaflex, Aveed, Edex |
| Sumitomo Pharma America, INC. | $485.65 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $396.84 | 2021-2025 | |
| Antares Pharma, INC. | $395.67 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $389.17 | 2019-2023 | Xtandi, Myrbetriq |
| Myovant Sciences INC. | $230.02 | 2021-2022 | |
| Neotract INC. | $222.87 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $202.44 | 2024-2025 | Prolaris, Myrisk |
| Pfizer INC. | $201.14 | 2019-2025 | |
| Endo USA, INC. | $159.27 | 2024-2025 | Xiaflex, Aveed |
| Coloplast Corp | $152.78 | 2019-2024 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $137.11 | 2021-2022 | |
| Amgen INC. | $123.46 | 2020-2022 | |
| Tolmar, INC. | $91.24 | 2023-2025 | Eligard, Jatenzo |
| Allergan, INC. | $87.54 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $86.63 | 2022-2025 | Welireg, Keytruda, Lynparza |
| 180 Medical, INC. | $78.39 | 2021-2025 | Gentlecath Glide |
| Novartis Pharmaceuticals Corporation | $69.48 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $64.59 | 2022-2023 | Oxlumo, Givlaari |
| Mission Pharmacal Company | $53.03 | 2019-2024 | Uribel, Uribel Tabs |
| Immunitybio, INC. | $49.01 | 2025 | |
| Clarus Therapeutics INC. | $48.42 | 2021 | |
| Blue Earth Diagnostics | $44.80 | 2020-2022 | |
| Boston Scientific Corporation | $39.37 | 2023 | Lithovue |
| Ferring Pharmaceuticals INC. | $38.79 | 2024-2025 | Adstiladrin |
| Baxter Healthcare | $35.79 | 2019-2021 | |
| Accord Healthcare, INC. | $32.76 | 2022-2023 | |
| Intuitive Surgical, INC. | $32.50 | 2022 | |
| Verity Pharmaceuticals INC. | $30.81 | 2025 | Tlando, Trelstar |
| Laborie Medical Technologies Corp. | $29.99 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $29.70 | 2023 | Botox |
| Axonics, INC. | $28.49 | 2022-2023 | Bulkamid |
| Calyxo, INC. | $26.26 | 2025 | Cvac Aspiration System |
| Ethicon US, LLC | $25.99 | 2021-2024 | Enseal, Echelon Flex |
| Progenics Pharmaceuticals, INC. | $25.82 | 2023 | Pylarify |
| Teleflex LLC | $23.71 | 2024 | Urolift |
| Rochester Medical Corporation | $19.35 | 2019 | |
| Hollister Incorporated | $18.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.05 | 2022 | |
| Abc Home Medical Supply, INC. | $17.66 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.41 | 2025 | |
| Convatec INC. | $17.01 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $16.24 | 2019 | |
| Telix Pharmaceuticals | $14.78 | 2024 | Illuccix |
| Dentsply Ih INC. | $14.42 | 2019 | |
| Ambu INC. | $13.91 | 2025 | |
| Sandoz INC. | $13.57 | 2025 | Jubbonti |
| Halozyme INC | $12.87 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Blaylock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.